Search

Phage Futures 2019 is next week! Even if you're not able to make it, we'll be posting tweets (#PhageFutures2019) and keeping you up to date on which speaker is speaking, what people's reactions are, and who's up next. Check out our Phage Fu

This week, we highlight a new paper documenting the first use of engineered phages in human therapy, published yesterday by Rebekah Dedrick, Carlos Guerrero-Bustamante, and colleagues in Nature Medicine. This week, we're going over a new ph

Silver Spring, MD ICON Government and Public Health Solutions specializes in preclinical through phase IV support of clinical research and clinical trial services for biologics, drugs, and devices. The candidate would perform research on ba

Dr. Sebastian Leptihn The Leptihn Group offers a Postdoctoral Fellowship: The project involves viruses of microbes (bacteriophages) with aspects on both function and structure of phage proteins, as well as phage therapy. Experience in imagi

I’m looking for phage typing collections of Enterobacteriaciae (eg. E. coli, Klebsiella, Salmonella) to pursue capsular variant-phage type correlation studies. Please email me at mike@aresinnovation.com or tweet @mkoeris to get in touch! Mi

CARB-X has announced its 2019 calls for proposals. Funding Round 1 covers non-traditional alternatives to antibiotics, including phage! Learn how to apply by tuning in May 16 for a webinar. Expressions of interest can be submitted June 3 –

You may recall reading about the discovery of arbitrium, a peptide produced by Bacillus phages to regulate lysogeny decisions. A new paper by Avigail Stokar-Avihail and colleagues in the Sorek lab at the Weizmann Institute has shown that ar

Ho Bin Jang, Benjamin Bolduc and colleagues from the Sullivan lab at Ohio State University, along with several collaborators from the US, UK, Canada, France, and Belgium, have published a paper this week in Nature Biotechnology describing a

The business combination transaction between AmpliPhi and C3J, two phage therapy biotech companies, is expected to close today. The new name of the combined company will be Armata Pharmaceuticals, Inc., and shares will be expected to start

The 26th Biennial Conference on Phage/Virus Assembly is happening July 14-19, 2019 at Cragun's Resort in Brainerd, Minnesota. Registration is open until May 30.

I’m looking for phage typing collections of Enterobacteriaciae (eg. E. coli, Klebsiella, Salmonella) to pursue capsular variant-phage type correlation studies. Please email me at mike@aresinnovation.com or tweet @mkoeris to get in touch! Mi

Silver Spring, MD ICON Government and Public Health Solutions specializes in preclinical through phase IV support of clinical research and clinical trial services for biologics, drugs, and devices. The candidate would perform research on ba

Dr. Sebastian Leptihn The Leptihn Group offers a Postdoctoral Fellowship: The project involves viruses of microbes (bacteriophages) with aspects on both function and structure of phage proteins, as well as phage therapy. Experience in imagi

CBS 60 Minutes covered superbugs this week. Buying colistin off the shelf, anyone?

Andrei Bolocan and colleagues from APC Microbiome, the University College Cork and the Teagasc Food Research Centre in Ireland have published a new review evaluating the prospects of E. faecalis phage therapy. They've categorized phages wit

A new paper (published today!) by Ann Gregory and colleagues shows identification of almost 200,000 new viral populations in the ocean (this work comes in part from the Tara Oceans expedition). The work identifies interesting new biodiversi

The same group that brought us the fascinating study on filamentous phage Pf's influence on P. aeruginosa virulence has published another study on the same phage. This time, they describe Pf prevalence (high) and implications (increased ant

Phigaro is a scalable command-line tool by Elizaveta Starikova and colleagues for phage and prophage prediction from nucleid acid sequences (including metagenomes). It can also produce annotated prophage genome maps and distinguish tailed f

A new phage product is now on the market! OmniLytics, Inc. and Certis USA have released AgriPhage™, which fights fire blight (Erwinia amylovora) in apple and pear crops. This is the first phage product approved for use against fire blight.

Micreos, a Dutch phage biotech company, secured 30 million Euro last month for its phage lysin technology. The company plans to use the funds for lysin development, and to launch its over-the-counter Gladskin product (anti-Staph aureus lysi